“Albireo has reached a new stage in its growth, and I am delighted to welcome two very high-caliber leaders to our board,” said
Dr. Klibanski is a recognized expert in the field of translational research, with a focus in rare diseases. She currently serves as the Laurie Carrol Guthart Professor of Medicine at
Ms. Okey brings more than 25 years of experience in the biopharmaceutical industry to Albireo’s board of directors. Most recently, she served as Senior Vice President,
In addition to these new appointments,
“On behalf of the board and leadership team, I’d like to thank Heather and Julia for their years of service and counsel,” said Dr. Chiswell. “Heather has been a valued member of the board since the inception of the company in 2008. She has played a fundamental role in moving the company toward our goal of being a leader in the treatment of liver disease. Julia has been an important contributor to our board after Albireo became a public entity following the merger with Biodel.”
With these additions, the current Albireo Board membership is as follows:
David Chiswell, Ph.D., Chairman of the Board, Albireo; CEO, Kymab Ron Cooper, President and CEO, Albireo Michael Gutch, Ph.D., Chief Business Officer and Chief Financial Officer, Entasis Therapeutics Roger Jeffs, Ph.D., former President and co-CEO, United Therapeutics
- Anne Klibanski, M.D., Laurie Carrol Guthart Professor of Medicine,
Harvard Medical School; Chief Academic Officer, Partners HealthCare Stephanie Okey, former Senior Vice President, Head of North America, Rare Diseases, and U.S. General Manager, Rare Diseases, Sanofi Genzyme Davey Scoon, Chair of the Board of Trustees, Allianz Global Investors
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
LifeSci Advisors, LLC.
Source: Albireo Pharma, Inc.